Sprouts Farmers Market Offering Info Hid Deflation, Says Securities Class Action

Prior to a public offering of stock, companies are required to disclose events or uncertainties, including any known trends, that may cause a change in future financial figures. The complaint for this securities class action alleges that Sprouts Farmers Market, Inc. compiled offering documents that did not meet this requirement and violated of the Securities  Read more

Sprouts Farmers Market Store Interior

Rewalk Did Not Disclose Risks Posed by Exoskeleton Use Study Securities Class Action

Complex medical devices are regulated by the Food and Drug Administration (FDA). If a company doesn’t have FDA approval for a device, it doesn’t have a product. The complaint for this securities class action claims that Rewalk Robotics Ltd. could not provide the FDA with an adequate plan for a post-market surveillance study of its  Read more

Rewalk Exoskeleton

Avinger Pantheris and Lumivascular Technology Unreliability Securities Class Action

The complaint for this class action alleges that Avinger, Inc. knew about problems with its products and technology by the time of its initial public offering (IPO) in January 2015, but did not disclose them in its Registration Statement or Prospectus, as required by the Securities Act of 1933. By the time it announced its  Read more

Avinger Lumivascular Technology

Sky Solar Holdings CEO Debt and Misleading Info for IPO Securities Class Action

Can the same person be essential to a company’s success and a liability to the company? The complaint for this class action alleges that the Registration Statement and Prospectus for Sky Solar Holdings, Inc.’s initial public offering (IPO) contained false and misleading statements about founder Weili Su as well as about the solar market and  Read more

Sky Solar Solar Panels

Apigee IPO Hid Competition, Revenue Declines Securities Class Action

It’s unfortunate that certain aspects of Apigee Corporation’s business were in decline or about to decline when it held its initial public offering (IPO), but the complaint for this class action alleges that Apigee negligently or deliberately hid this fact from investors, in violation of Sections 11 and 15 of the Securities Act of 1933.  Read more

Forterra Withheld Material Info in Its IPO Filings, Says Securities Class Action

Investors make decisions based largely on what a company’s financial information indicates about its future operating results. However, if “events and uncertainties” exist that might cause a company’s future results to be very different, its SEC filings must reveal them. The complaint for this class action claims that Forterra’s filings for its initial public offering  Read more

Qudian IPO Registration Statement Omitted Info Securities Class Action

Eight underwriters were involved in Qudian’s initial public offering (IPO), but the complaint for this class action claims that the Registration Statement they caused to be filed was misleading, omitting critical information in two respects, (1) in discussing the company’s collection practices and (2) in discussing its data systems and procedures. The complaint alleges that  Read more

Tintri Misleading IPO Registration Statement Securities Class Action

When Tintri, Inc. decided to go public, it made the required filings of Registration Statement and Prospectus with the Securities and Exchange Commission (SEC). The initial public offering (IPO) raised $60 million for the company, but the complaint for this class action claims the filings contained false and misleading statements, in violation of Sections 11  Read more

OvaScience IPO Filings Augment Treatment Information Hiding Class Action

With women preferring to have children at later ages, successful fertility treatments are a promising product, even for a company that has not yet earned any revenue. According to the complaint, however, OvaScience, Inc. made misrepresentations about its Augment procedure in the Registration Statement for its initial public offering (IPO), in violation of Sections 11,  Read more

Novan IPO and Misleading Info on Acne Drug Securities Class Action

Novan, a drug development company, was testing a drug for acne vulgaris when it held its initial public offering (IPO) on September 26, 2016. The complaint for this class action claims that Novan’s public statements omitted important information, for example that two “identically-designed” drug trials were not in fact identical, leading investors to believe that  Read more